Teva Pharmaceutical Industries Limited (TEVA)
USD 21.2
(1.53%)
USD 21.2
(1.53%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 4.33 Billion USD | 3.95% |
| 2022 | -874 Million USD | -9.34% |
| 2021 | 4.4 Billion USD | -1.78% |
| 2020 | -2.09 Billion USD | 43.48% |
| 2019 | 1.27 Billion USD | 1.68% |
| 2018 | 186 Million USD | -39.11% |
| 2017 | -15.51 Billion USD | 11.56% |
| 2016 | 2.86 Billion USD | -9.03% |
| 2015 | 6.34 Billion USD | 13.9% |
| 2014 | 5.97 Billion USD | 13.36% |
| 2013 | 3.2 Billion USD | -32.35% |
| 2012 | 3.88 Billion USD | 46.01% |
| 2011 | 4.25 Billion USD | -15.17% |
| 2010 | 4.82 Billion USD | 26.83% |
| 2009 | 2.4 Billion USD | 225.5% |
| 2008 | 1.14 Billion USD | -58.48% |
| 2007 | 2.39 Billion USD | -28.06% |
| 2006 | 2.52 Billion USD | 146.5% |
| 2005 | 1.55 Billion USD | -23.05% |
| 2004 | 1.39 Billion USD | 119.74% |
| 2003 | 1.01 Billion USD | 51.1% |
| 2002 | 524 Million USD | 23.21% |
| 2001 | 485.58 Million USD | -0.39% |
| 2000 | 470.19 Million USD | 80.42% |
| 1999 | 335.89 Million USD | 21.82% |
| 1998 | 262.47 Million USD | -4.0% |
| 1997 | 225.79 Million USD | 27.77% |
| 1996 | 173 Million USD | 30.96% |
| 1995 | 137.2 Million USD | 10.46% |
| 1994 | 134.3 Million USD | 21.03% |
| 1993 | 107.6 Million USD | 42.22% |
| 1992 | 72.8 Million USD | 13.69% |
| 1991 | 65.9 Million USD | 24.57% |
| 1990 | 52.9 Million USD | 19.41% |
| 1989 | 44.3 Million USD | 46.2% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 928 Million USD | -97.03% |
| 2024 Q2 | 1.07 Billion USD | 464.44% |
| 2023 Q2 | 979 Million USD | 20.42% |
| 2023 Q1 | 813 Million USD | -22.5% |
| 2023 FY | - USD | 3.95% |
| 2023 Q4 | 1.45 Billion USD | 38.85% |
| 2023 Q3 | 1.04 Billion USD | 6.74% |
| 2022 Q3 | 993 Million USD | -4.89% |
| 2022 Q1 | 1.01 Billion USD | -18.73% |
| 2022 FY | - USD | -9.34% |
| 2022 Q2 | 1.04 Billion USD | 3.26% |
| 2022 Q4 | 1.04 Billion USD | 5.64% |
| 2021 Q3 | 1.03 Billion USD | -4.5% |
| 2021 FY | - USD | -1.78% |
| 2021 Q2 | 1.08 Billion USD | -3.72% |
| 2021 Q4 | 1.24 Billion USD | 19.73% |
| 2021 Q1 | 1.13 Billion USD | 1.25% |
| 2020 FY | - USD | 43.48% |
| 2020 Q3 | 1.08 Billion USD | 0.93% |
| 2020 Q4 | 1.11 Billion USD | 3.05% |
| 2020 Q2 | 1.07 Billion USD | -19.57% |
| 2020 Q1 | 1.33 Billion USD | -46.01% |
| 2019 Q2 | 1.12 Billion USD | 4.06% |
| 2019 FY | - USD | 1.68% |
| 2019 Q1 | 1.08 Billion USD | 120.33% |
| 2019 Q3 | 1.11 Billion USD | -1.51% |
| 2019 Q4 | 2.47 Billion USD | 122.41% |
| 2018 FY | - USD | -39.11% |
| 2018 Q1 | 1.62 Billion USD | -19.91% |
| 2018 Q2 | 841 Million USD | -48.12% |
| 2018 Q4 | 492 Million USD | -55.99% |
| 2018 Q3 | 1.11 Billion USD | 32.94% |
| 2017 Q2 | 1.67 Billion USD | 2.76% |
| 2017 Q4 | 2.02 Billion USD | 43.14% |
| 2017 Q3 | 1.41 Billion USD | -15.68% |
| 2017 FY | - USD | 11.56% |
| 2017 Q1 | 1.63 Billion USD | 28.91% |
| 2016 FY | - USD | -9.03% |
| 2016 Q1 | 1.56 Billion USD | 31.07% |
| 2016 Q2 | 1.18 Billion USD | -24.54% |
| 2016 Q3 | 1.56 Billion USD | 32.18% |
| 2016 Q4 | 1.26 Billion USD | -18.9% |
| 2015 Q4 | 1.19 Billion USD | -26.75% |
| 2015 FY | - USD | 13.9% |
| 2015 Q3 | 1.63 Billion USD | -1.09% |
| 2015 Q2 | 1.64 Billion USD | 1.54% |
| 2015 Q1 | 1.62 Billion USD | 37.08% |
| 2014 Q3 | 1.53 Billion USD | 5.0% |
| 2014 FY | - USD | 13.36% |
| 2014 Q1 | 1.46 Billion USD | 41.45% |
| 2014 Q2 | 1.45 Billion USD | -0.34% |
| 2014 Q4 | 1.18 Billion USD | -22.72% |
| 2013 Q3 | 1.43 Billion USD | 8.33% |
| 2013 FY | - USD | -32.35% |
| 2013 Q1 | 1.34 Billion USD | 1.05% |
| 2013 Q2 | 1.32 Billion USD | -1.71% |
| 2013 Q4 | 1.03 Billion USD | -27.67% |
| 2012 Q1 | 1.59 Billion USD | 8.13% |
| 2012 Q4 | 1.33 Billion USD | -10.32% |
| 2012 Q3 | 1.48 Billion USD | -1.2% |
| 2012 Q2 | 1.5 Billion USD | -5.95% |
| 2012 FY | - USD | 46.01% |
| 2011 FY | - USD | -15.17% |
| 2011 Q4 | 1.47 Billion USD | 9.5% |
| 2011 Q1 | 1.16 Billion USD | -14.87% |
| 2011 Q2 | -373 Million USD | -132.1% |
| 2011 Q3 | 1.34 Billion USD | 461.39% |
| 2010 Q1 | 868 Million USD | -4.62% |
| 2010 FY | - USD | 26.83% |
| 2010 Q4 | 1.36 Billion USD | -9.0% |
| 2010 Q3 | 1.5 Billion USD | 40.06% |
| 2010 Q2 | 1.07 Billion USD | 23.39% |
| 2009 Q2 | 959 Million USD | 35.26% |
| 2009 Q1 | 709 Million USD | 171.62% |
| 2009 FY | - USD | 225.5% |
| 2009 Q3 | 850 Million USD | -11.37% |
| 2009 Q4 | 910 Million USD | 7.06% |
| 2008 Q2 | 759 Million USD | -36.0% |
| 2008 Q4 | -990 Million USD | -222.98% |
| 2008 FY | - USD | -58.48% |
| 2008 Q1 | 1.18 Billion USD | 48.06% |
| 2008 Q3 | 805 Million USD | 6.06% |
| 2007 Q4 | 801 Million USD | 4.71% |
| 2007 Q1 | 583 Million USD | 5.01% |
| 2007 FY | - USD | -28.06% |
| 2007 Q2 | 767 Million USD | 31.56% |
| 2007 Q3 | 765 Million USD | -0.26% |
| 2006 Q3 | 833.7 Million USD | 0.37% |
| 2006 Q1 | 1.64 Billion USD | 355.45% |
| 2006 FY | - USD | 146.5% |
| 2006 Q4 | 555.2 Million USD | -33.41% |
| 2006 Q2 | 830.6 Million USD | -49.51% |
| 2005 Q1 | 386.4 Million USD | 15.21% |
| 2005 Q4 | 361.2 Million USD | 15.7% |
| 2005 Q3 | 312.2 Million USD | 1.17% |
| 2005 Q2 | 308.6 Million USD | -20.13% |
| 2005 FY | - USD | -23.05% |
| 2004 Q2 | 297.1 Million USD | -65.08% |
| 2004 FY | - USD | 119.74% |
| 2004 Q4 | 335.4 Million USD | 5.57% |
| 2004 Q3 | 317.7 Million USD | 6.93% |
| 2004 Q1 | 850.8 Million USD | 275.63% |
| 2003 Q1 | 179.3 Million USD | 2.93% |
| 2003 Q4 | 306.7 Million USD | 14.92% |
| 2003 FY | - USD | 51.1% |
| 2003 Q3 | 197.1 Million USD | 4.12% |
| 2003 Q2 | 189.3 Million USD | 5.58% |
| 2002 Q3 | 121.4 Million USD | 10.46% |
| 2002 Q2 | 109.9 Million USD | 3.19% |
| 2002 Q4 | 174.2 Million USD | 43.49% |
| 2002 Q1 | 106.5 Million USD | -16.07% |
| 2002 FY | - USD | 23.21% |
| 2001 Q1 | 76.84 Million USD | -54.72% |
| 2001 Q3 | 96.5 Million USD | 13.75% |
| 2001 Q2 | 84.83 Million USD | 10.41% |
| 2001 FY | - USD | -0.39% |
| 2001 Q4 | 126.89 Million USD | 31.49% |
| 2000 Q1 | 53.06 Million USD | -13.88% |
| 2000 FY | - USD | 80.42% |
| 2000 Q3 | 74.42 Million USD | -41.48% |
| 2000 Q4 | 175.95 Million USD | 128.01% |
| 2000 Q2 | 93.45 Million USD | 139.67% |
| 1999 Q2 | 41.2 Million USD | 7.29% |
| 1999 Q1 | 38.4 Million USD | -48.39% |
| 1999 Q4 | 61.61 Million USD | -5.5% |
| 1999 FY | - USD | 21.82% |
| 1999 Q3 | 65.2 Million USD | 58.25% |
| 1998 Q1 | 33.3 Million USD | 105.11% |
| 1998 FY | - USD | -4.0% |
| 1998 Q2 | 20.9 Million USD | -37.24% |
| 1998 Q3 | 38.2 Million USD | 82.78% |
| 1998 Q4 | 45.9 Million USD | 94.76% |
| 1997 Q2 | 270.7 Million USD | 1.16% |
| 1997 FY | - USD | 27.77% |
| 1997 Q3 | 286.7 Million USD | 5.91% |
| 1997 Q4 | -651.2 Million USD | -327.14% |
| 1997 Q1 | 267.6 Million USD | 148.94% |
| 1996 Q4 | -546.8 Million USD | -331.11% |
| 1996 Q3 | 236.6 Million USD | -5.44% |
| 1996 Q2 | 250.2 Million USD | 32.17% |
| 1996 Q1 | 189.3 Million USD | 152.64% |
| 1996 FY | - USD | 30.96% |
| 1995 Q1 | 152.7 Million USD | 147.66% |
| 1995 Q3 | 165.3 Million USD | 5.42% |
| 1995 Q2 | 156.8 Million USD | 2.69% |
| 1995 FY | - USD | 10.46% |
| 1995 Q4 | -359.6 Million USD | -317.54% |
| 1994 Q1 | 136.7 Million USD | 148.36% |
| 1994 FY | - USD | 21.03% |
| 1994 Q4 | -320.4 Million USD | -323.28% |
| 1994 Q3 | 143.5 Million USD | -2.31% |
| 1994 Q2 | 146.9 Million USD | 7.46% |
| 1993 Q4 | -282.7 Million USD | -322.25% |
| 1993 Q3 | 127.2 Million USD | 1.76% |
| 1993 Q1 | 118.4 Million USD | 154.11% |
| 1993 FY | - USD | 42.22% |
| 1993 Q2 | 125 Million USD | 5.57% |
| 1992 Q4 | -218.8 Million USD | -335.27% |
| 1992 Q2 | 93 Million USD | 0.11% |
| 1992 Q1 | 92.9 Million USD | 148.31% |
| 1992 Q3 | 93 Million USD | 0.0% |
| 1992 FY | - USD | 13.69% |
| 1991 Q2 | 77.8 Million USD | -10.88% |
| 1991 Q4 | -192.3 Million USD | -344.35% |
| 1991 Q1 | 87.3 Million USD | 158.67% |
| 1991 Q3 | 78.7 Million USD | 1.16% |
| 1991 FY | - USD | 26.21% |
| 1990 FY | - USD | 0.98% |
| 1990 Q1 | 65.7 Million USD | 143.34% |
| 1990 Q2 | 69.6 Million USD | 5.94% |
| 1990 Q3 | 62.6 Million USD | -10.06% |
| 1990 Q4 | -148.8 Million USD | -337.7% |
| 1989 Q3 | 63.8 Million USD | -7.27% |
| 1989 Q2 | 68.8 Million USD | 0.88% |
| 1989 Q1 | 68.2 Million USD | 155.81% |
| 1989 Q4 | -151.6 Million USD | -337.62% |
| 1989 FY | - USD | 74.06% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 500.78 Million USD | -765.247% |
| Bausch Health Companies Inc. | 2.88 Billion USD | -50.191% |
| Catalent, Inc. | -284 Million USD | 1625.704% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 957.51% |
| Elanco Animal Health Incorporated | -224 Million USD | 2034.375% |
| Perrigo Company plc | 646.2 Million USD | -570.535% |
| Zoetis Inc. | 3.68 Billion USD | -17.585% |